The Filing Desk

Precision Biosciences vs Entrada Therapeutics

Precision Biosciences DTIL · Entrada Therapeutics TRDA · Biotechnology

Precision Biosciences reported revenue of $34 million in fiscal 2025, 1.4 times Entrada Therapeutics' $25 million in fiscal 2025. Precision Biosciences' revenue fell 50.1% in its latest year, and Entrada Therapeutics' fell 87.9%. Precision Biosciences had an operating margin of -152.2%, against -621.1% at Entrada Therapeutics. Free cash flow was −$66 million at Precision Biosciences and −$130 million at Entrada Therapeutics.

Side by side

Precision BiosciencesEntrada Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$34M$25M
Revenue growth−50.1%−87.9%
Revenue growth a year, last 5 years7.1%—
Gross margin——
Operating margin−152.2%−621.1%
Net margin−133.4%−565.5%
Free cash flow−$66M−$130M
Free cash flow margin−192.4%−509.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count86.3%6.1%
Last close$6.91$4.64
P/E at the last close——
Insider trades, last 12 monthsbought $63,215, sold $412,359bought $291,124, sold $6.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Precision BiosciencesEntrada Therapeutics
Operating margin
Percent of revenue
Precision BiosciencesEntrada Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Precision BiosciencesEntrada Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Precision Biosciences and Entrada Therapeutics pages.